Periostin

1 paper3 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

1 lab in 1 country

Funders: National Natural Science Foundation of China and 1 more

Cells1

Outcomes

Osteogenic differentiation potential

upin rat cells1

1 study

Periostin improves osteogenic differentiation potential in rat cells.
“exogenous POSTN supplementation enhanced cell viability, mitigated ROS accumulation, alleviated cellular senescence, and ameliorated autophagic flux and osteogenic capacity in these cells.”
Cellsin normal and T2DM rat BMSCs
Periostin ameliorates impaired osteogenic differentiation of bone marrow mesenchymal stem cells from T2DM rats via modulating autophagy and cellular senescence
International immunopharmacology12 Feb 2026

Autophagy

upin rat cells1

1 study

Periostin increases autophagy in rat cells.
“exogenous POSTN supplementation enhanced cell viability, mitigated ROS accumulation, alleviated cellular senescence, and ameliorated autophagic flux and osteogenic capacity in these cells.”
Cellsin normal and T2DM rat BMSCs
Periostin ameliorates impaired osteogenic differentiation of bone marrow mesenchymal stem cells from T2DM rats via modulating autophagy and cellular senescence
International immunopharmacology12 Feb 2026

Latest

1 in 12 months

International Immunopharmacology14 Feb

Periostin ameliorates impaired osteogenic differentiation of bone marrow mesenchymal stem cells from T2DM rats via modulating autophagy and cellular senescence

Experiments in rat cellsType 2 diabetes

Paper

Periostin

Outcomes

Latest

Periostin ameliorates impaired osteogenic differentiation of bone marrow mesenchymal stem cells from T2DM rats via modulating autophagy and cellular senescence

Related